Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 1667 results found since Jan 2013.

Ultrasound-Mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment via Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes
CONCLUSION: UMND enhanced PLGA-PEI NBs-STAT6 siRNA to repolarize TAMs from the M2 to the M1 phenotype, thus treating NSCLC. These findings provide a promising therapeutic approach for enhancing NSCLC immunotherapy.PMID:37491853 | DOI:10.2174/1567201820666230724151545
Source: Current Drug Delivery - July 26, 2023 Category: Drugs & Pharmacology Authors: Hong Shu Wenhao Lv Zhi-Jian Ren Hui Li Tiantian Dong Yao Zhang Fang Nie Source Type: research

In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models.
In this study, we report the use of siRNA/RGD gold nanoparticles capable of targeting tumor cells in a lung cancer syngeneic orthotopic murine model. Therapeutic RGD-nanoparticle treatment resulted in successful targeting evident from significant c-myc oncogene down-regulation followed by tumor growth inhibition and prolonged survival of lung tumor bearing mice, possibly via αvβ3 integrin interaction. Our results suggest that RGD gold nanoparticles-mediated delivery of siRNA by intratracheal instillation in mice leads to successful suppression of tumor cell proliferation and respective tumor size reduction. These results...
Source: Biomaterials - July 12, 2013 Category: Materials Science Authors: Conde J, Tian F, Hernández Y, Bao C, Cui D, Janssen KP, Ibarra MR, Baptista PV, Stoeger T, de la Fuente JM Tags: Biomaterials Source Type: research

Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy.
In this study, we developed a Lipid/Calcium/Phosphate (LCP) nanoparticle that combines chemotherapy with gene therapy. By encapsulating a chemodrug, gemcitabine monophosphate (GMP), and siRNA specific to the undruggable cMyc oncogene (cMyc siRNA) into a single nano-sized vesicle and systemically administering them to nude mice, we achieved potent anti-tumor activity in both subcutaneous and orthotopic models of NSCLC. The improvements in therapeutic response over either cMyc siRNA or GMP therapy alone, were demonstrated by the ability to effectively induce the apoptosis of tumor cells and the significant reduction of proli...
Source: Biomaterials - August 8, 2013 Category: Materials Science Authors: Zhang Y, Peng L, Mumper RJ, Huang L Tags: Biomaterials Source Type: research

Downregulation of ABCE1 via siRNA affects the sensitivity of A549 cells against chemotherapeutic agents
In conclusion, the simultaneous treatment of lung cancer cells with ABCE1 siRNA and 5-FU exhibited synergistic or additive effects; however, ABCE1 siRNA and irinotecan had unexpected antagonistic effects. Our findings demonstrate that the strategy of downregulation of ABCE1 may be included in conventional 5-FU chemotherapy for lung cancer, minimizing the usage of 5-FU at high dosages.
Source: Medical Oncology - March 6, 2015 Category: Cancer & Oncology Source Type: research

Inhibition of IL-8-mediated endothelial adhesion, VSMCs proliferation and migration by siRNA-TMEM98 suggests TMEM98's emerging role in atherosclerosis.
Authors: Lv G, Zhu H, Li C, Wang J, Zhao D, Li S, Ma L, Sun G, Li F, Zhao Y, Gao Y Abstract Transmembrane protein 98 (TMEM98), known as a novel gene related to lung cancer, hepatocellular carcinoma, differentiation of T helper 1 cells and normal eye development, has no defined role reported in terms of atherosclerosis (AS). To investigate the potential involvement of TMEM98 during AS processes, its obvious secretion and expression has been initially characterized in hyperlipidemia patients' serum and AS mice's serum respectively. We then explored the possible role of TMEM98 in the pathogenesis of AS in vitro. IL-8,...
Source: Oncotarget - November 22, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer
CONCLUSION: The results showed that the PDL1-targeted albumin liposome could be used as a high efficient delivery vector of siRNA, and was a high efficient and safe nano vector for tumor targeted gene therapy.PMID:35997823 | DOI:10.1007/s00432-022-04298-2
Source: Cell Research - August 23, 2022 Category: Cytology Authors: Liming Zhang Guangke Xie Xin Xiao Chao Cheng Source Type: research

Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery
This study verifies the successful spray drying procedure of LNP-siRNA systems maintaining their integrity and mediating strong gene silencing efficiency on mRNA and protein levels both in vitro and ex vivo. The successful spray drying procedure of LNP-siRNA formulations in 5% lactose solution creates a novel siRNA-based therapy option to target respiratory diseases such as lung cancer, asthma, COPD, cystic fibrosis and viral infections.PMID:36126785 | DOI:10.1016/j.jconrel.2022.09.021
Source: Cancer Control - September 20, 2022 Category: Cancer & Oncology Authors: Christoph M Zimmermann Domizia Baldassi Karen Chan Nathan B P Adams Alina Neumann Diana Leidy Porras-Gonzalez Xin Wei Nikolaus Kneidinger Mircea Gabriel Stoleriu Gerald Burgstaller Dominik Witzigmann Paola Luciani Olivia M Merkel Source Type: research

Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer
ConclusionThe results showed that the PDL1-targeted albumin liposome could be used as a high efficient delivery vector of siRNA, and was a high efficient and safe nano vector for tumor targeted gene therapy.
Source: Journal of Cancer Research and Clinical Oncology - July 1, 2023 Category: Cancer & Oncology Source Type: research

Application of Target Peptide in siRNA Delivery 
for the Research of Lung Cancer Therapy
This article will make a brief overview of target peptides applying in siRNA dilivery for the research of lung cancer treatment. DOI: 10.3779/j.issn.1009-3419.2014.09.06
Source: Chinese Journal of Lung Cancer - September 19, 2014 Category: Cancer & Oncology Source Type: research

Abstract 718: Systemic delivery of therapeutic siRNA by multifunctional mesoporous silica-based nanocarrier inhibits lung cancer growth and metastasis
In this study, we developed a novel siRNA delivery vector based on our magnetic mesoporous silica nanoparticles (M-MSNs) platform. This nanocarrier was constructed by loading siRNAs into the mesopores of M-MSNs, followed by polyethylenimine (PEI) capping, PEGylation and fusogenic peptide KALA modification. The resultant functionalized delivery system exhibited prolonged half-life in bloodstream, enhanced cell membrane translocation and endosomal escapablity, and favorable tissue biocompatibility and biosafety. Systemic application of vascular endothelial growth factor (VEGF) siRNA via this nanocarrier resulted in remarkabl...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Chen, Y., Gu, H., Xia, W. Tags: Experimental and Molecular Therapeutics Source Type: research

Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA.
Abstract Small interfering RNA (siRNA)-mediated gene silencing represents a promising strategy for treating diseases such as cancer; however, specific gene silencing requires an effective delivery system to overcome the instability and low transfection efficiency of siRNAs. To address this issue, a polysorbitol-based transporter (PSOT) was prepared by low molecular-weight branched polyethylenimine (bPEI) crosslinked with sorbitol diacrylate (SDA). Osteopontin (OPN) gene, which is highly associated with non-small cell lung cancer (NSCLC) was targeted by siRNA therapy using siRNA targeting OPN (siOPN). Characterizat...
Source: European Journal of Pharmaceutics and Biopharmaceutics - June 30, 2015 Category: Drugs & Pharmacology Authors: Cho WY, Hong SH, Singh B, Islam MA, Lee S, Lee AY, Gankhuyag N, Kim JE, Yu KN, Kim KH, Park YC, Cho CS, Cho MH Tags: Eur J Pharm Biopharm Source Type: research

Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer
ConclusionsCo-treatment of lipid-modified compounds andsurvivin-silencing siRNA can constitute a reliable alternative to cisplatin treatment for cisplatin-resistant lung tumors that merit further evaluation.
Source: Pharmaceutical Research - November 3, 2016 Category: Drugs & Pharmacology Source Type: research